Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03914794 · ClinicalTrials.gov registry record · Phase 2

A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

A Phase 2 study of Bladder Cancer and Non-muscle Invasive Bladder Cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Completed
Registry status
Phase 2
Development phase
30
Enrollment target
6
Study locations

NCT03914794 is a Phase 2 study of Bladder Cancer and Non-muscle Invasive Bladder Cancer that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 30 participants, below the 12,754-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower). The trial reports 6 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03914794, a Phase 2 study of Bladder Cancer and Non-muscle Invasive Bladder Cancer, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

COMPLETED
Registry status
Phase 2
Development phase
30 participants
Enrollment target
6
Study locations

Study Summary

This phase II trial studies how well Pemigatinib (an orally administered inhibitor of fibroblast growth factor receptors 1, 2, and 3) works in non-muscle invasive bladder cancer (NMIBC) patients with recurrent tumors and a prior history of low- or intermediate-risk NMIBC tumors. Participants will receive pemigatinib for 4-6 weeks prior to standard of care transurethral resection of bladder tumor (TURBT).

Conditions Studied

Bladder Cancer Non-muscle Invasive Bladder Cancer NMIBC Urothelial Carcinoma Recurrent

Interventions

  • DRUG Pemigatinib

Study Locations (6)

Pennsylvania

  • Midlantic Urology - Bala-Cynwyd
  • Keystone Urology - Lancaster

District of Columbia

  • Sibley Memorial Hospital - Washington D.C.

Maryland

  • Johns Hopkins School of Medicine - Sidney Kimmel Comprehensive Cancer Center - Baltimore

New York

  • Associated Medical Professionals Urology - Syracuse

South Carolina

  • Carolina Urologic Research Center - Myrtle Beach

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2020-10-02
Est. Completion 2025-09-30
Phase Phase 2

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

523 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03914794

The ClinicalTrials.gov registry entry for NCT03914794 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,754-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower). The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Bladder Cancer appearing as the primary indexed condition, and to 1 intervention - of which Pemigatinib is the first listed.

NCT03914794 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Pennsylvania, District of Columbia, Maryland.

Frequently Asked Questions

What is clinical trial NCT03914794 about?

NCT03914794 is a clinical study titled "A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors". This phase II trial studies how well Pemigatinib (an orally administered inhibitor of fibroblast growth factor receptors 1, 2, and 3) works in non-muscle invasive bladder cancer (NMIBC) patients with recurrent tumors and a prior history of low- or intermediate-risk NMIBC tumors. Participants will re...

What is the current status of trial NCT03914794?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2020-10-02. Estimated completion is 2025-09-30.

What conditions does trial NCT03914794 study?

This clinical trial studies the following conditions: Bladder Cancer, Non-muscle Invasive Bladder Cancer, NMIBC, Urothelial Carcinoma Recurrent.

What interventions are being tested in trial NCT03914794?

The interventions under investigation include: Pemigatinib (DRUG).

Who is sponsoring clinical trial NCT03914794?

This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03914794 being conducted?

This trial has 6 study locations across District of Columbia, Maryland, New York, Pennsylvania, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Bladder Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Bladder Cancer

All registered trials for this condition

Non-muscle Invasive Bladder Cancer

All registered trials for this condition

District of Columbia

All trials with a study site in District of Columbia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.